Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

Key Inclusion Criteria: * Be able to understand and sign a written informed consent or assent form, which must be obtained prior to initiation of study procedures. * Postmenopausal women are allowed to participate in this study * Body mass index (BMI) ≥ 18.5 to \< 39 kilograms (kg)/square meter (m\^2) * Have an activating mutation of the Calcium-sensing receptor (CASR) gene * Participants being treated with thiazide diuretics may be enrolled if they are willing and able to discontinue thiazides * Participants being treated with strong Cytochrome P3A4 (CYP3A4) inhibitors should ideally, if clinically appropriate, discontinue these medications during the screening period * Participants being treated with magnesium or potassium citrate supplements should discontinue such treatment starting on Day -1 during Period 1 and Period 2 and may be asked to discontinue treatment during Period 3 Key Exclusion Criteria: * History of treatment with parathyroid hormone (PTH) 1-84 or 1-34 within the previous 3 months * History of hypocalcemic seizure within the past 3 months * Blood 25-OH Vitamin D level \< 25 nanograms (ng)/milliliter (mL) * Participants with hemoglobin (Hgb) \< 13 grams (g)/deciliter (dL) for men and \< 12 g/dL for women * Estimated glomerular filtration rate (eGFR) \< 25 mL/minute/1.73 m\^2 using Chronic Kidney Disease Epidemiology Collaboration (for participants \<18 years old the Schwartz equation will be calculated) * 12-lead resting electrocardiogram (ECG) with clini…